{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-210413","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.578641+00:00","generated_at":"2026-05-14T21:45:42.049829+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara biotherapeutics gets FDA alignment on tab-cel BLA resubmission path","bullets":["Type A meeting with FDA was productive; FDA agreed single-arm study with historical control could support future application.","Pierre Fabre to submit updated ALLELE study dataset with more patients and longer follow-up as part of resubmission.","Tabelecleucel is for R/R EBV+ PTLD post solid organ or hematopoietic cell transplant.","Company expects to provide further regulatory update in Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-210413","json":"https://secwatch.observer/filing/0001193125-26-210413.json","markdown":"https://secwatch.observer/filing/0001193125-26-210413.md","text":"https://secwatch.observer/filing/0001193125-26-210413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/0001193125-26-210413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526210413/atra-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:45:42.049829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}